Pacific Biosciences of California, Inc.
$878.66M- Market cap
- $413.40M
- Debt
- +$744.76M
- Cash
- −$279.51M
Capital structure 36% equity / 64% debt · EV / Revenue 5.49x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PACB stock price at discount vs RVMD $1.33 current versus $2.00K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVMD's multiple
Implied fair value · at PACB's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PACB FY 2025 (ended Dec 31, 2025) · RVMD FY 2023 (ended Dec 31, 2023). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 36% equity / 64% debt · EV / Revenue 5.49x
Capital structure 100% equity / 0% debt · EV / Revenue 3744.77x
RVMD carries the larger enterprise value at $43.36B against $878.66M; PACB trades on the lower EV / Revenue multiple (5.49x vs 3744.77x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Pacific Biosciences of California, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
139.23x
0.11x
Net debt / EBITDA
Leverage against operating earnings
-3.07x
3.85x
Cash and equivalents
Liquid reserves on the balance sheet
$279.51M
$1.85B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ILLUMINA, INC.
PACB vs ILMN
THERMO FISHER SCIENTIFIC INC.
PACB vs TMO
AGILENT TECHNOLOGIES, INC.
PACB vs A
DANAHER CORP /DE/
PACB vs DHR
REVVITY, INC.
PACB vs RVTY
AMGEN INC
PACB vs AMGN
BRISTOL MYERS SQUIBB CO
PACB vs BMY
GILEAD SCIENCES, INC.
PACB vs GILD
INCYTE CORP
PACB vs INCY
VERTEX PHARMACEUTICALS INC / MA
PACB vs VRTX
Moderna, Inc.
PACB vs MRNA
$744.76M
$193.93M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.